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OBJECTIVES: To investigate whether the improved well-
being and quality of life (QoL) and decreased use of
healthcare resources seen during the ﬁrst year of GH sub-
stitution therapy in GH-deﬁcient adults are maintained
over subsequent years of treatment.
METHODS: Data were analysed from 237 Swedish
hypopituitary adults with GH deﬁciency (GHD) who had
received 2 (n = 196) or 3 (n = 130) years of GH replace-
ment therapy (mean dose, 0.43mg/day). All patients (117
men, 120 women; mean age at baseline, 51.5 years; range,
35–69 years; 141 (60%) with at least three additional
hormone deﬁciencies, and 16 with isolated GHD) were
included in KIMS (Pharmacia International Metabolic
Database)—a pharmacoepidemiological survey of adults
with GHD. None had previously received GH replace-
ment in childhood. Eighty-ﬁve (36%) had had <10 years
of formal education; 142 (60%) were in full or part-
time work, and 39 (17%) had taken early retirement or
were receiving a disability pension. QoL was assessed
using AGHDA—a disease-speciﬁc questionnaire—and
the generic PGWB index. Information on the patients’
social situation and well-being was obtained from a
patient life situation form. Statistical analysis was by
repeated measurements regression.
RESULTS: A signiﬁcant subjective improvement in well-
being was noted by 78% of patients after 1 year and by
86% after 3 years. QoL (both AGHDA and PGWB)
showed statistically signiﬁcant improvements after 1 
year, which were sustained for up to 3 years. The VAS
score for leisure-time activity also increased signiﬁcantly
during the whole follow-up period, as did patients’ satis-
faction with their level of physical activity. Use of health-
care resources (days of reported sick-leave and doctor
visits) decreased signiﬁcantly during the ﬁrst year of 
treatment.
CONCLUSIONS: Three years of GH treatment in adults
with GHD has a sustained positive effect on well-being,
QoL and physical activity, and decreases the consumption
of healthcare resources.
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Studies in healthy volunteers and renal transplant 
recipients indicated that Gengraf (Abbott: cyclosporine
capsule, USP Modiﬁed), had less negative attributes than
Neoral (cyclosporine capsule, USP Modiﬁed). Prior
research indicated patient dissatisfaction with smell, odor,
taste and size of CsA capsules.
OBJECTIVE: The objective of the PREFER Study was 
to evaluate CsA capsule preference using a validated CsA
Capsule Satisfaction Survey (CCSS) that measured the
impact of CsA’s attributes: odor, swallowability, taste,
breath and body odor on patient satisfaction.
METHOD: 1932 stable, solid-organ transplant recipients
(294 heart; 1420 kidney; 154 liver; 64 other) taking
stable doses of Neoral were randomized to Gengraf or
Neoral, (9 :1) on day 1. Subjects completed a pre-
randomization, day 1, baseline CCSS and day 28, Final
CCSS.
RESULTS: Subjects switched to Gengraf showed statisti-
cally signiﬁcant improvement of the six CsA Capsule
attributes and expressed preference for Gengraf over
Neoral. P-values for satisfaction of subjects switched to
Gengraf from Neoral were <0.001 in each of the attrib-
utes of capsule odor, swallowability, taste, halitosis, body
odor, and overall score. Final preference outcomes of the
CCSS showed the preference for Gengraf over Neoral 
in the attributes studied as follows (equal preferences 
not shown): 66.3% versus 7% for capsule odor, 51.5%
versus 6.7% for swallowability, 57.1% versus 6.5% for
taste, 52.5% versus 5.8% for associated halitosis, and
48.4% versus 5.3% for associated body odor. Based on
overall experience, 61.9% preferred Gengraf and 13.7%
preferred Neoral.
CONCLUSION: In conclusion, in this study, when com-
paring CsA attributes of odor, ease of swallowing, taste,
halitosis, and body odor, transplant patients prefer
Gengraf to Neoral. Further evaluation is necessary to
determine the impact on long-term compliance.
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